Search research articles
Contact Us
Filters
Showing results (51-60 of 58) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 58 results.
Der Pathologe
|
September 1, 1992
[Classification of erosions of the stomach. Results of a meeting of the Study Group of Gastroenterologic Pathology of the German Society of Pathology 23 November 1991 in Frankfurt/Main]
F Borchard, P Malfertheiner, A von Herbay, et al.
Journal of Hematotherapy
|
October 1, 1995
G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210)
R Repp, T Valerius, G Wieland, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
March 29, 2002
Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma
R Burger, A Guenther, F Bakker, et al.
Physical Chemistry Chemical Physics : PCCP
|
April 7, 2007
Intermediate temperature proton conductors for PEM fuel cells based on phosphonic acid as protogenic group: a progress report
H Steininger, M Schuster, K D Kreuer, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
July 31, 1998
Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer
G G Grabenbauer, H Steininger, M Meyer, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 10, 2000
Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy
G G Grabenbauer, C Mühlfriedel, F Rödel, et al.
British Journal of Cancer
|
August 13, 2009
Angiogenesis and lymphangiogenesis are downregulated in primary breast cancer
E-M Boneberg, D F Legler, M M Hoefer, et al.
British Journal of Cancer
|
December 17, 2003
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer
R Repp, H H van Ojik, T Valerius, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 58) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 58 results.
Der Pathologe
|
September 1, 1992
[Classification of erosions of the stomach. Results of a meeting of the Study Group of Gastroenterologic Pathology of the German Society of Pathology 23 November 1991 in Frankfurt/Main]
F Borchard, P Malfertheiner, A von Herbay, et al.
Journal of Hematotherapy
|
October 1, 1995
G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210)
R Repp, T Valerius, G Wieland, et al.
The Hematology Journal : the Official Journal of the European Haematology Association
|
March 29, 2002
Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma
R Burger, A Guenther, F Bakker, et al.
Physical Chemistry Chemical Physics : PCCP
|
April 7, 2007
Intermediate temperature proton conductors for PEM fuel cells based on phosphonic acid as protogenic group: a progress report
H Steininger, M Schuster, K D Kreuer, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
July 31, 1998
Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer
G G Grabenbauer, H Steininger, M Meyer, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 10, 2000
Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy
G G Grabenbauer, C Mühlfriedel, F Rödel, et al.
British Journal of Cancer
|
August 13, 2009
Angiogenesis and lymphangiogenesis are downregulated in primary breast cancer
E-M Boneberg, D F Legler, M M Hoefer, et al.
British Journal of Cancer
|
December 17, 2003
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer
R Repp, H H van Ojik, T Valerius, et al.
Page
of 6